The H1 2026 results show a sharp but fragile turnaround, with the $4.8M licensing revenue masking a $3.0M decline in core device sales. The cash position ($289K) is critically low despite the ~$4M September convertible note. Watch for the sustainability of licensing revenue in H2 2026 and any further deterioration in device sales or accounts receivable aging.
Price Chart
Executive Summary
Baird Medical reported H1 2026 unaudited results showing a dramatic turnaround from a net loss of $11.4M in H1 2025 to a net income of $13,499 in H1 2026, driven by $4.8M in new technology licensing revenue. However, core MWA device sales declined by $3.0M, and cash and restricted cash fell to just $289K. The company subsequently raised ~$4M via a convertible note in September 2026. The prior annual report flagged a 39% drop in core MWA device sales and a material weakness in internal controls, making this interim improvement fragile and heavily reliant on the new licensing initiative.
Key Facts
- Revenue increased 24.6% YoY to $9.9M in H1 2026 from $8.0M in H1 2025, driven by $4.8M in new technology licensing revenue.
- Core MWA device sales declined by $3.0M YoY, with distributor sales down $0.8M and direct customer sales down $2.2M.
- Net income of $13,499 in H1 2026 vs. net loss of $11.4M in H1 2025; operating income swung to +$0.8M from -$10.5M.
- Cash and restricted cash fell to $289K as of June 30, 2026, from $566K at Dec 31, 2025.
- Company raised ~$4M via a 12-month, 8% OID convertible note in September 2026, classified as a current liability.
- Working capital declined to $10.2M from $22.6M at Dec 31, 2025.
- Accounts receivable over a year old increased to $31.8M from $19.9M; allowance for credit losses rose to $5.8M.
- Management concluded no substantial doubt about going concern, citing financial support from CEO and related party.
- Prior 20-F (April 2026) reported a 39% drop in core MWA device sales for FY2025 and a material weakness in internal controls.
Financial Impact
Revenue $9.9M (H1 2026) vs $8.0M (H1 2025); net income $13,499 vs net loss $11.4M; cash position $289K; ~$4M convertible note raised post-period.
Risk Factors
- Core MWA device sales continue to decline, down $3.0M YoY in H1 2026.
- Cash and restricted cash of $289K is critically low; the ~$4M convertible note provides only near-term relief.
- Accounts receivable over a year old surged to $31.8M, with allowance for credit losses rising to $5.8M.
- Working capital nearly halved to $10.2M from $22.6M at year-end 2025.
- Prior material weakness in internal controls and auditor change raise governance concerns.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-112109 |
| Document: bdmd-20260930x6k.htm | 0001104659-26-112109 |
| Document: bdmd-ex99d2.htm | 0001104659-26-112109 |
| Document: 0001104659-26-112109-index-headers.html | 0001104659-26-112109 |
| Document: 0001104659-26-112109-index.html | 0001104659-26-112109 |
| Document: 0001104659-26-112109.txt | 0001104659-26-112109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 6-K | $0.7440 | awaiting T+20 | — | $0.2819 (+62.11%) |
Sep 30, 2026 27d ago | 6-K | $0.7800 | awaiting T+20 | — | $0.2819 (−63.86%) |
Sep 3, 2026 7w ago | 6-K | $1.17 $0.7511 | ▼ −35.80% | ▼ −34.62% | $0.2819 (−75.91%) |
Sep 3, 2026 7w ago | Press Release | $1.17 $0.7511 | ▼ −35.80% | ▼ −34.62% | $0.2819 (−75.91%) |
Aug 18, 2026 10w ago | EFFECT | $1.09 $1.06 | ▲ +2.75% | ▲ +1.76% | $0.2819 (+74.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers